🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Contribution of GFAP and UCH-L1 Assays in Whole Blood to Optimizing Personalized Care for "Repeated Fallers" Hospitalized in Geriatric Wards

RecruitingNAAges 75 Years - anyAllUniversity Hospital, Clermont-Ferrand
NCT07342023 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The BACHUS study focuses on a population of patients aged 75 years and older who are hospitalized after recurrent falls. The objective is to evaluate the performance of an innovative, personalized biological screening strategy to detect intracranial hemorrhages, as an alternative to brain CT scanning, which is often difficult to access within the required time frame in elderly patients. Patients included in the study will undergo two blood measurements of the biomarkers GFAP and UCH-L1 performed on whole blood using a portable device such as the i-Stat Alinity. The first measurement will be performed within 72 hours of admission in order to establish an individual baseline value, given the impossibility of relying on average reference values in this population, which is subject to variability in biomarker levels due to confounding factors. In the event of a new fall during hospitalizat

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Hospitalized patients aged 75 years and older, cared for in the short-stay geriatric unit at Guy Thomas Hospital in Riom * Recurrent fallers (more than one fall per week) * Informed consent from the patient or their designated representative for patients unable to write but capable of understanding and consenting to participate in the study * Enrollment in a Social Security health insurance scheme Exclusion Criteria: * Fall occurring before the reference biomarker measurement * Presence of an intracranial hemorrhage confirmed by CT scan at admission * Ischemic or hemorrhagic stroke * Inability to perform the two blood samples required by the protocol due to very limited venous access * End-of-life situation * Adults under legal protection (guardianship, curatorship, deprivation of liberty, or judicial protection)
💊

What it tests

  • blood sampling
📍

Where

1 site
Ch de Riom
Riom, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy